Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H7X7

UPID:
IFT22_HUMAN

ALTERNATIVE NAMES:
Rab-like protein 5

ALTERNATIVE UPACC:
Q9H7X7; Q49AG1; Q69YV5; Q9BSW4

BACKGROUND:
The Intraflagellar transport protein 22 homolog, alternatively named Rab-like protein 5, is integral to the IFT complex B, functioning as a small GTPase-like component. It is vital for ciliogenesis and the proper functioning of cilia, which are key for cellular signaling and locomotion.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Intraflagellar transport protein 22 homolog offers a promising avenue for drug discovery. Given its critical role in cilia formation and maintenance, targeting this protein could lead to innovative treatments for diseases linked to ciliary dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.